2013 Life Sciences Private Equity Dealmaking Symposium
Join West Monroe as we discuss how to manage the complexity of deal activity in the life sciences industry
Date : October 3, 2013 Time : 11:00 AM CST
McDermott Will & Emery’s second annual Life Sciences Private Equity Dealmaking Symposium will focus on the opportunities and challenges for those investing and operating in the multibillion dollar life sciences industry. The event will feature a seasoned panels of private equity, investment bank, pharmaceutical, biotechnology, and medical products and services leaders who will provide insight and guidance into how to address the ever-changing landscape.

Matt Sondag will speak on the Quality of Earnings Issues in Medical Product Transactions panel.

This panel will discuss the following:

  • Which transactions or other circumstances dictate that buyers engage a third party to complete a rigorous quality of earnings analysis
  • At what stage of the deal process should a buyer initiate its quality of earnings analysis relative to some of the other buyer diligence requirements for the transaction
  • What historical and prospective time periods should be considered in the quality of earnings analysis and why
  • What tend to be the biggest quality of earnings traps and surprises for buyers of medical products businesses
  • What items having an impact on earnings are commonly overlooked by sellers in presenting target financial information to prospective buyers

This event is being held at the Ritz Carlton Chicago.

11:00 AM – 5:30 PM CDT – Program

5:30 – 7:30 PM CDT – Reception

For more information, please click here.

West Monroe Insights
Non-Revenue Water (NRW): Challenges & Solutions
View More
Related Insights
Matt Barnes will present at Mergermarket’s Life Sciences and Healthcare M&A forum
Date : July 13, 2017 Time : 08:30 AM EST
Join West Monroe’s Matt Barnes at Mergermarket’s Life Sciences and Healthcare M&A forum as he discusses the science behind pharma mergers.
New York
How pharma companies can facilitate higher quality patient care at a lower cost.
Date : May 19, 2017
Pharmaceutical companies that have adopted a patient-centric approach have seen significant benefits in the form of greater patient adherence to medication, more consistent customer engagement, and overall improvements in the efficiency of their medical information and pharmacovigilance operations.
Natural Language Generation Goes to Work
Date : January 24, 2017

Natural Language Generation (NLG) is a form of artificial intelligence (AI) which takes an input of data and produces a narrative similar to how a human would interpret the data. NLG technology can be very transformative when used in business situations, especially in industries that are heavily dependent on generating text summaries based on straightforward conclusions drawn from structured data and that lack the capital to support a large workforce.